Patent
C-aryl glucoside SGLT2 inhibitors
Reads0
Chats0
TLDR
In this paper, a method for treating diabetes and related diseases employing an SGLT2 inhibiting amount of the above compound alone or in combination with another antidiabetic agent or other therapeutic agent.Abstract:
SGLT2 inhibiting compounds are provided having formula (I) where R?1, R2, and R2a? are independently hydrogen, OH, OR5, lower alkyl, CF?3?, OCHF2, OCF3, SR?5i? or halogen, or two of R?1, R2 and R2a? together with the carbons to which they are attached can form an annelated five, six or seven membered carbocycle or heterocycle; R?3 and R4? are independently hydrogen, OH, OR5a, OAryl, OCH?2?Aryl, lower alkyl, cycloalkyl, CF3, -OCHF2, -OCF3, halogen, -CN, -CO2R?5b, -CO?2H, -COR6b, -CH(OH)R6c, -CH(OR?5h)R6d, -CONR6R6a?, -NHCOR5c, -NHSO?2R?5d, -NHSO?2?Aryl, Aryl, -SR?5e, -SOR5f, SO?2R5g, SO2Aryl, or a five, six or seven membered heterocycle, or R?3 and R4? together with the carbons to which they are attached form an annelated five, six or seven membered carbocycle or heterocycle; R?5, R5a, R5b, R5c, R5d, R5e, R5f, R5g, R5h, and R5I? are independently lower alkyl; R?6, R6a, R6b, R6c and R6d? are independently hydrogen, alkyl, aryl, alkylaryl or cycloalkyl, or R?6 and R6a? together with the nitrogen to which they are attached form an annelated five, six or seven membered heterocycle; A is O, S, NH, or (CH?2?)n where n is 0 - 3. A method is also provided for treating diabetes and related diseases employing an SGLT2 inhibiting amount of the above compound alone or in combination with another antidiabetic agent or other therapeutic agent.read more
Citations
More filters
Patent
Albumin Fusion Proteins
TL;DR: The present invention encompasses albumin fusion proteins as discussed by the authors, as well as vectors containing these nucleic acids, host cells transformed with the nucleic acid vectors, and methods of making the fusion proteins of the invention.
Patent
C-aryl glucoside SGLT2 inhibitors and method
TL;DR: In this article, an SGLT2 inhibiting compound is provided having the formula having the chemical structure, and a method is also provided for treating diabetes and related diseases employing an sGLT 2 inhibiting amount of the above compound alone or in combination with another antidiabetic agent or other therapeutic agent.
Patent
Methods of producing c-aryl glucoside sglt2 inhibitors
Prashant P. Deshpande,Bruce A. Ellsworth,Janak Singh,Theodor Denzel,Chiajen Lai,Gerard A. Crispino,Michael E. Randazzo,Jack Z. Gougoutas +7 more
TL;DR: In this paper, a method for the production of C-aryl glucoside SGLT2 inhibitors useful for the treatment of diabetes and related diseases is presented. But this method requires the use of amino acid complex forming reagents.
Patent
Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
TL;DR: In this paper, the authors defined Glucopyranosyl-substituted benzene derivatives of general formula I where the groups R 1 to R 6 as well as R 7a, R 7b, R7c are defined herein and the tautomers, the stereoisomers thereof, the mixtures thereof and the salts thereof.
Patent
C-glycoside derivatives and salts thereof
Masakazu Imamura,Takeshi Murakami,Ryota Shiraki,Kazuhiro Ikegai,Takashi Sugane,Fumiyoshi Iwasaki,Eiji Kurosaki,Hiroshi Tomiyama,Noda Atsushi,Kayoko Kitta,Kobayashi Yoshinori +10 more
TL;DR: A C-glycoside derivative represented by the following general formula (I) or its salt which is a compound useful as a Na+glucose co-transportation inhibitor in a remedy for, e.g., diabetes, in particular, insulin-independent diabetes (type 2 diabetes) and insulin dependent diabetes(type 1 diabetes), as well as a remedy remedy for insulin resistance diseases and various diseases relating to diabetes including obesity as discussed by the authors.
References
More filters
Patent
Aryl c-glycoside compounds and sulfated esters thereof
Sato Susumu,Takeshi Kuribayashi,Shigeru Ushiyama,Takashi Yasumoto,Kazuhiko Tanzawa,Masaaki Takahashi +5 more
TL;DR: An aryl C-glycoside of formula (I) is a natural or artificial monosaccharide having an α or β bond or a disac-charide, trisac-decaride or tetrasaccharides as mentioned in this paper.
Patent
Genes and proteins predictive and therapeutic for stroke, hypertension, diabetes and obesity
TL;DR: In this paper, genes whose expression is modulated in SHR-rats, which is an animal model for human metabolic X syndrome, are revealed and methods of diagnosing or treating conditions associated with metabolic X disorders using these genes and gene products.
Patent
Hypoglycemic dihydrochalcone derivatives
Kenji Tsujihara,Mitsuya Tanabe Seiyaku Omiya-Ryo Hongu,Funami Nobuyuki,Inamasu Masanori,Kenji Arakawa +4 more
TL;DR: A hypoglycemic agent which comprises as an active ingredient a dihydrochalcone derivative of the formula [I] is defined in this paper, wherein Ar is an aryl group, R is a hydrogen atom or an acyl group, and OR is a protected or unprotected hydroxy group or lower alkoxy group.
Journal ArticleDOI
C-glycosylated aryl tins: versatile building blocks for aryl c-glycoside glycomimetics
TL;DR: C-glycosylated aryl tins have been prepared as versatile building blocks of physiologically stable glycomimetics for glycoepitopes that have been recognized to serve biologically important roles in cell biochemistry.
Journal ArticleDOI
Circular dichroism of c-glycosylflavones : A chiroptical method for differentiating 6-C-,8-C- and 6,8-Di-C-β-glycosyl isomers
TL;DR: In this article, a quadrant rule based on the substituted benzoyl chromophore was proposed to explain the chiroptical properties of C-β-glycosylflavones.